

REMARKS

The Official Action has required the applicants to elect a single invention and designate a single Subgroup for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held allowable.

Applicants hereby elect with traverse, Group I, Claims 1-3.


Applicants have also been asked to select a single disclosed Subgroup consisting of not more than five Seq. IDs. Applicants select the species of Seq. ID. 1-5.

In addition, in response to the requirement to designate claims readable on the designated species, applicants further submit that claims 1-3 are readable on the designated species.

The above designations are made with the understanding that this application is not limited to the designated species, and with the understanding that upon allowance of a claim generic to the designated species, applicants will be entitled to examination in this application of additional species.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicant
Reg. No. 36,214

Date: August 1, 2007